Biosimilar adalimumab for patients with active rheumatoid arthritis
76
0
2023-11-10 16:12
Progressive descending facial nerve paralysis in amyloidosis
Fragile X-associated tremor or ataxia syndrome
Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab
Always use containment morcellation bags
The Carbon Cost of Healthcare
Efficacy and safety of treating alopecia areata with ritlecitinib
Stridor from birth indicates congenital upper airway obstruction
Launch of The Lancet 2023 Series on Breastfeeding
0 bullet chats
Please Sign In first
Unauthorized reproduction is prohibited
Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center in Dallas, Texas, presents a study of multiple switches between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis.
The study was published in The Lancet Rheumatology in August 2023.
Comments 0
Please to post a comment~
Loading...
Related Suggestion